Drugs / CKD-386
CKD-386
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05552495 | Sep → Nov 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04694989 | Feb → Apr 2021 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04673864 | Jan → Mar 2021 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04223895 | Feb → Mar 2020 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03920579 | Apr → May 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673864 ↗ |
| Known as | CKD-386 F1 | “CKD-386 F1” NCT04223895 ↗ |
| Known as | CKD-386 Formulation 1 | “Drug: CKD-386 Formulation 1” NCT04223895 ↗ |
| Known as | CKD-386 Formulation 2 | “Drug: CKD-386 Formulation 2” NCT04223895 ↗ |
| Route | Oral | “A single oral dose of 1 tablet under fasting conditions for each period” NCT03920579 ↗ |